EPOPROSTENOL FOR INJECTION 0.5 MG
EPOPROSTENOL (EPOPROSTENOL SODIUM) : 0.5 MG · DIN 02345706 · SANDOZ CANADA INCORPORATED
Health Canada status: CANCELLED PRE MARKET
What is EPOPROSTENOL FOR INJECTION?
EPOPROSTENOL FOR INJECTION 0.5 MG contains EPOPROSTENOL (EPOPROSTENOL SODIUM) : 0.5 MG. It is listed in the Health Canada Drug Product Database under DIN 02345706, held by SANDOZ CANADA INCORPORATED, supplied as POWDER FOR SOLUTION for INTRAVENOUS administration. Health Canada currently lists it as cancelled pre market, status dated 21-Apr-2021. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is EPOPROSTENOL FOR INJECTION used for?
Epoprostenol for Injection (epoprostenol sodium) is indicated for the long-term intravenous treatment of idiopathic or heritable pulmonary arterial hypertension (PAH) or PAH associated with connective tissue diseases (CTD) in patients with WHO Functional Class III-IV symptoms who did not respond adequately to conventional therapy. Prior to initiation of therapy, the potential benefit of Epoprostenol for Injection should be weighed against the risks associated with use of the drug and the presence of an indwelling central venous catheter.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02345706 |
|---|---|
| Brand name | EPOPROSTENOL FOR INJECTION |
| Generic / active ingredient | EPOPROSTENOL (EPOPROSTENOL SODIUM) : 0.5 MG |
| Manufacturer | SANDOZ CANADA INCORPORATED |
| Strength | 0.5 MG |
| Dosage form | POWDER FOR SOLUTION |
| Route of administration | INTRAVENOUS |
| Schedule | Prescription |
| ATC code | B01AC09 EPOPROSTENOL |
| AHFS class | 84:80.00 |
| Biosimilar | No |
| Health Canada status | CANCELLED PRE MARKET |
| Status date | 21-Apr-2021 |
| Original market date | 2010-04-23 00:00:00 |
How is it stored and handled?
null
How is it supplied?
null
What can be used instead?
Other Canadian products sharing ATC code B01AC09 EPOPROSTENOL. 4 of 6 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| CARIPUL | 0.5 MG | POWDER FOR SOLUTION | JANSSEN INC | MARKETED | DIN 02397447 |
| CARIPUL | 1.5 MG | POWDER FOR SOLUTION | JANSSEN INC | MARKETED | DIN 02397455 |
| FLOLAN | 0.5 MG | POWDER FOR SOLUTION | GLAXOSMITHKLINE INC | MARKETED | DIN 02230845 |
| FLOLAN | 1.5 MG | POWDER FOR SOLUTION | GLAXOSMITHKLINE INC | MARKETED | DIN 02230848 |
| EPOPROSTENOL FOR INJECTION | 1.5 MG | POWDER FOR SOLUTION | SANDOZ CANADA INCORPORATED | CANCELLED PRE MARKET | DIN 02345714 |
Who else supplies EPOPROSTENOL worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. EPOPROSTENOL appears in 14 registered pack listings across 5 markets, published on 5 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.